Australian TGA Approves Illuccix® for Prostate Cancer Imaging
MELBOURNE, Australia, Nov. 01, 2021 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has approved Illuccix® (TLX591-CDx), the Company’s lead prostate cancer imaging product. Illuccix (Kit for the